Source 1review2024Small Methods
Toolkit/OptoDroplet
OptoDroplet
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
OptoDroplet is an optogenetic multi-component switch that controls biomolecular phase separation by fusing disease-associated proteins to light-sensitive oligomerization domains. Light input enables induction or reversal of condensate formation with spatial and temporal control.
Usefulness & Problems
Why this is useful
This tool is useful for experimentally controlling condensate assembly dynamics in living systems with light. The cited literature specifically describes its use for dissecting mechanisms of neurodegenerative disease through optogenetic manipulation of phase separation.
Source:
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
Problem solved
OptoDroplet addresses the problem of how to perturb biomolecular phase separation in a controlled, reversible, and spatiotemporally precise manner. In the cited context, it helps probe how condensate formation by disease-associated proteins contributes to neurodegenerative disease mechanisms.
Source:
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
Problem links
Need precise spatiotemporal control with light input
DerivedOptoDroplet is an optogenetic multi-component switch used to control biomolecular phase separation by fusing disease-associated proteins to light-sensitive oligomerization domains. It enables induction or reversal of condensate formation with spatial and temporal control and has been used to dissect mechanisms of neurodegenerative disease.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Techniques
No technique tags yet.
Target processes
No target processes tagged yet.
Input: Light
Implementation Constraints
application domain: intracellular LLPS controlcofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: multi component delivery burdenimplementation constraint: spectral hardware requirementmodality: optogeneticmodality: optogenetic condensate controloperating role: actuatorswitch architecture: multi component
Implementation involves fusion of disease-associated proteins to light-sensitive oligomerization domains to confer optogenetic control over phase separation. The provided evidence does not report construct architecture details, cofactors, delivery methods, or expression systems.
The supplied evidence does not specify the exact light-sensitive oligomerization domains, illumination wavelengths, host systems, or quantitative performance metrics. Independent replication and validation outside the cited review context are not established from the provided material.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2025MED
Ranked Claims
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
optoDroplet, Corelet, PixELL, and CasDrop are highlighted as intracellular systems that enable photo-mediated control over biomolecular condensation.
Among these, the intracellular systems (i.e., optoDroplet, Corelet, PixELL, CasDrop, and other optogenetic systems) that enable the photo-mediated control over biomolecular condensation are highlighted.
Approval Evidence
2 sources3 linked approval claimsfirst-pass slug optodroplet
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
Source:
Among these, the intracellular systems (i.e., optoDroplet, Corelet, PixELL, CasDrop, and other optogenetic systems) that enable the photo-mediated control over biomolecular condensation are highlighted.
Source:
application scopesupports
OptoDroplet is being used to dissect mechanisms of neurodegenerative disease.
This review highlights how optogenetic systems such as OptoDroplet are being used to dissect the mechanisms of neurodegenerative disease.
Source:
mechanism of actionsupports
Optogenetic control of phase separation is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling induction or reversal of condensate formation with spatial and temporal control.
This is achieved by fusing disease-associated proteins to light-sensitive oligomerization domains, enabling researchers to induce or reverse condensate formation with precise spatial and temporal control.
Source:
tool class membershipsupports
optoDroplet, Corelet, PixELL, and CasDrop are highlighted as intracellular systems that enable photo-mediated control over biomolecular condensation.
Among these, the intracellular systems (i.e., optoDroplet, Corelet, PixELL, CasDrop, and other optogenetic systems) that enable the photo-mediated control over biomolecular condensation are highlighted.
Source:
Comparisons
Source-backed strengths
A key strength is optical control over condensate induction or reversal with spatial and temporal precision. The available evidence supports its application to disease-associated proteins and to mechanistic studies of neurodegenerative disease.
Compared with AQTrip EL222 variant
OptoDroplet and AQTrip EL222 variant address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: oligomerization; same primary input modality: light
Compared with OptoLoop
OptoDroplet and OptoLoop address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: oligomerization; same primary input modality: light
Compared with optoRET
OptoDroplet and optoRET address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: oligomerization; same primary input modality: light
Ranked Citations
- 1.
- 2.